BLS empanelled to process Ayushman Bharat cards
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
ICMR receives conditional exemption from Drone Rules 2021 to speed up vaccine delivery in the A&N Islands, Manipur and Nagaland
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
The much-awaited drone delivery trials for the delivery of medicines and vaccines will be held in Vikarabad, Hyderabad from 9th September till 17th October.
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Subscribe To Our Newsletter & Stay Updated